Neuroblastoma: Issues in Transplantation

Overview

Journal Biol Blood Marrow Transplant

Date 2012 Jan 10

PMID 22226119

Citations 5

Authors

Stephan A Grupp

Shahab Asgharzadeh

Gregory A Yanik

Affiliations

Soon will be listed here.

Citing Articles

Cancer stem cells in neuroblastoma therapy resistance.

Aravindan N, Jain D, Somasundaram D, Herman T, Aravindan S Cancer Drug Resist. 2019; 2:948-967.

PMID: 31867574 PMC: 6924637. DOI: 10.20517/cdr.2019.72.

-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-G immunotherapy.

Kushner B, LaQuaglia M, Modak S, Wolden S, Basu E, Roberts S Oncotarget. 2017; 8(56):95293-95302.

PMID: 29221128 PMC: 5707022. DOI: 10.18632/oncotarget.20513.

Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2,....

Talleur A, Triplett B, Federico S, Mamcarz E, Janssen W, Wu J Biol Blood Marrow Transplant. 2017; 23(11):1910-1917.

PMID: 28733263 PMC: 5682204. DOI: 10.1016/j.bbmt.2017.07.011.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner B, Ostrovnaya I, Cheung I, Kuk D, Modak S, Kramer K Oncotarget. 2015; 7(4):4155-66.

PMID: 26623730 PMC: 4826196. DOI: 10.18632/oncotarget.6393.

Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Cheung N, Dyer M Nat Rev Cancer. 2013; 13(6):397-411.

PMID: 23702928 PMC: 4386662. DOI: 10.1038/nrc3526.

References

Kletzel M, Katzenstein H, Haut P, Yu A, Morgan E, Reynolds M . Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002; 20(9):2284-92. DOI: 10.1200/JCO.2002.06.060. View

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View

Philip T, Ladenstein R, Zucker J, Pinkerton R, Bouffet E, Louis D . Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer. 1993; 67(1):119-27. PMC: 1968211. DOI: 10.1038/bjc.1993.21. View

Seeger R, Reynolds C, Gallego R, Stram D, Gerbing R, Matthay K . Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2000; 18(24):4067-76. DOI: 10.1200/JCO.2000.18.24.4067. View

Matthay K, OLeary M, Ramsay N, VILLABLANCA J, Reynolds C, Atkinson J . Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995; 31A(4):572-5. DOI: 10.1016/0959-8049(95)00015-b. View

George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

Schmidt M, Lal A, Seeger R, Maris J, Shimada H, OLeary M . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005; 23(27):6474-80. DOI: 10.1200/JCO.2005.05.183. View

Parisi M, Greene M, Dykes T, Moraldo T, Sandler E, Hattner R . Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol. 1992; 27(10):768-73. DOI: 10.1097/00004424-199210000-00003. View

Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-23. PMC: 2993160. DOI: 10.1056/NEJMoa1001527. View

10.

Cheung N, Kushner B, Kramer K . Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am. 2002; 15(5):853-66. DOI: 10.1016/s0889-8588(05)70255-0. View

11.

Dini G, Philip T, Hartmann O, Pinkerton R, Chauvin F, Garaventa A . Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant. 1989; 4 Suppl 4:42-6. View

12.

Bagatell R, Rumcheva P, London W, Cohn S, Look A, Brodeur G . Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005; 23(34):8819-27. DOI: 10.1200/JCO.2004.00.2931. View

13.

Bown N, Cotterill S, Lastowska M, ONeill S, Pearson A, Plantaz D . Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340(25):1954-61. DOI: 10.1056/NEJM199906243402504. View

14.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

15.

Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y . Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol. 2010; 28(21):3506-15. DOI: 10.1200/JCO.2009.27.3367. View

16.

Matthay K . Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant. 1996; 18 Suppl 3:S21-4. View

17.

Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L . PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol. 2008; 26(33):5443-9. DOI: 10.1200/JCO.2007.13.6531. View

18.

Pearson A, Pinkerton C, Lewis I, Imeson J, Ellershaw C, Machin D . High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008; 9(3):247-56. DOI: 10.1016/S1470-2045(08)70069-X. View

19.

Wieland D, Mangner T, Inbasekaran M, Brown L, Wu J . Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984; 27(2):149-55. DOI: 10.1021/jm00368a008. View

20.

Seeger R, Vo D, Ugelstad J, Reynolds C . Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res. 1986; 211:285-93. View